Results 1 to 10 of about 871,767 (407)

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy

Journal of Hematology & Oncology, 2019
Angiogenesis has always been the topic of major scientific interest in the field of malignant tumors. Nowadays, targeting angiogenesis has achieved success in various carcinomas by several mechanisms, including the use of anti-angiogenic small molecule ...
Shuang Qin, Anping Li, Ming Yi, Shengnan Yu, Mingsheng Zhang, Kongming Wu   +5 more
semanticscholar   +1 more source

Erythropoietin-induced serine 727 phosphorylation of STAT3 in erythroid cells is mediated by a MEK-, ERK-, and MSK1-dependent pathway [PDF]

, 2003
Objective. Erythropoietin (EPO) is a key regulator of erythropoiesis, playing a role in both the proliferation and differentiation of erythroid cells.
Bieber, Boer, Chung, Decker, Gabrilove, Gonzalez, Goodnough, Gotoh, Haq, Jain, Jain, Jonk, Kaptein, Kirito, Kirito, Kirito, Lim, Millot, Miyazaki, Mulcahy, Ng, Schuringa, Schuringa, Schuringa, Smithgall, Socolovsky, Teglund, Tilbrook, Turkson, Watowich, Wen, Wen, Woetmann, Yokogami, Youssoufian, Yu, Zhang   +36 more
core   +1 more source

Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

Tumor Biology, 2017
The finding of epidermal growth factor receptor tyrosine kinase inhibitors, which reflects a classical process of translational research, is a critical milestone for non-small-cell lung cancer treatment.
Shaohua Cui, Liyan Jiang
doaj   +1 more source

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

Haematologica, 2013
Response to tyrosine kinase inhibitors at three months is a predictor for long-term outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Aziz Nazha, Hagop Kantarjian, Preetesh Jain, Carlos Romo, Elias Jabbour, Alfonso Quintas-Cardama, Raja Luthra, Lynne Abruzzo, Gautam Borthakur, Farhad Ravandi, Sherry Pierce, Susan O’Brien, Jorge Cortes   +12 more
doaj   +1 more source

Evidence of the presence of calcium/calmodulin-dependent protein kinase IV in human sperm and its involvement in motility regulation [PDF]

, 2005
The mechanisms involved in the regulation of mammalian sperm motility are not well understood. Calcium ions (Ca(2+)) have been suggested to play a key role in the maintenance of motility; nevertheless, how Ca(2+) modulates this process has not yet been ...
Buffone, Mariano Gabriel, Chertihin, Olga, Herr, John C,, Jha, Kula N., Marin Briggiler, Clara Isabel, Vazquez, Monica Hebe, Visconti, Pablo E.   +6 more
core   +1 more source

Activation of tyrosine kinases by mutation of the gatekeeper threonine. [PDF]

, 2008
Protein kinases targeted by small-molecule inhibitors develop resistance through mutation of the gatekeeper threonine residue of the active site. Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth ...
Azam, Mohammad, Daley, George, Gray, Nathanael, KURIYAN, John, Seeliger, Markus   +4 more
core   +1 more source

Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap

Frontiers in Pharmacology, 2020
Systemic mastocytosis is a rare and heterogeneous disease characterized by mast cell proliferation and activation. KIT is a transmembrane tyrosine kinase which plays a key role in mast cell growth, differentiation and survival. After interaction with its
Miguel Piris-Villaespesa, Ivan Alvarez-Twose   +1 more
doaj   +1 more source

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I [PDF]

, 2012
Background: Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity.
Badura, Susanne, Khateb, Mamduh, Mahajna, Jamal, Metodieva, Anna, Mian, Afsar Ali, Najajreh, Yousef, Ottmann, Oliver Gerhard, Ruimi, Nili, Ruthardt, Martin   +8 more
core   +1 more source

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

Molecular Cancer, 2018
Protein tyrosine kinase (PTK) is one of the major signaling enzymes in the process of cell signal transduction, which catalyzes the transfer of ATP-γ-phosphate to the tyrosine residues of the substrate protein, making it phosphorylation, regulating cell ...
Qinlian Jiao, Lei Bi, Yidan Ren, Shuliang Song, Qin Wang, Yunshan Wang   +5 more
semanticscholar   +1 more source

Tyrosine kinase inhibitors for the therapy of anaplastic thyroid cancer [PDF]

, 2015
Anaplastic thyroid cancer (ATC) is often incurable so new therapeutic approaches are needed. Tyrosine kinases inhibitors (such as imanitib, sunitinib or sorafenib) are under evaluation for the treatment of ATC.
Bond JA, Cohen EE, Dowlati A, Goulart B, Grande E, Hayashi N, Ibrahim N, Klopper JP, Mahlknecht U, Ohta K, Ruggeri RM, Sherman SI   +11 more
core   +1 more source